Functional Pulmonary Capillary Surface Area in BPA for CTEPH

Recruiting now · Not applicable

Conditions studied: Hypertension, Pulmonary, Pulmonary Thromboembolisms

In brief

Chronic thromboembolic pulmonary hypertension \[CTEPH\] is caused by pulmonary emboli that have enlarged in pulmonary arteries and have become organized into the vessel wall. Many patients with CTEPH are treated with balloon pulmonary angioplasty \[BPA\] which mechanically opens the narrow pulmonary arteries. It is unclear how much downstream functional pulmonary capillary surface area \[FCSA\] is recovered during BPA. The investigators plan to measure FCSAIn CTEPH patients, before and after a session of BPA.

Key facts

Study ID

NCT05719415

Run by

Jewish General Hospital

People needed

40

Starts

2023-03-23

Expected to finish

2028-01-30

Last updated by the study team

2025-09-23

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All patients eligible for balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension

You may not qualify if…

• Treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers,
• Presence of patent foramen ovale

Where it is running

• David Langleben — Montreal, Quebec, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.